ClinicalTrials.gg
RecruitingNCT07739160Updated Nov 5, 2026

The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

A Phase 2 interventional study of HRS-4029 and Placebo in Acute Ischemic Stroke, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
240th of 563
340 · median 266
Started
2026
with 121 others
Phase 2
71 of 750
29 open now
Primary completion
2027-04
later than 198 of 395 live
Registered
718th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 240th largest by planned enrollment of the 563 interventional ones that give a count, is one of 122 that started in 2026, is one of 71 in phase 2, reaches primary completion later than 198 of the 395 other live ones, and was the 718th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand and voluntarily participate in this trial, and sign the form (the informed consent form can be signed voluntarily by the participant or their legal representative).
  2. Stroke onset within 3 hours prior to screening, and expected to receive study drug administration within 3 hours after stroke onset.
  3. Clinical diagnosis of acute ischemic stroke (AIS).
  4. Modified Rankin Scale (mRS) score ≤1 prior to stroke onset.
  5. National Institutes of Health Stroke Scale (NIHSS) score of 6 to 25 at screening, and the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2.

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhagic diseases, including but not limited to hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc..
  2. Severe impairment of consciousness: NIHSS Item 1a (Level of Consciousness) score ≥ 2.
  3. Concurrent other neurological/psychiatric disorders (e.g., Parkinsonism, epilepsy, severe cognitive impairment, severe depression, etc.) that render the patient uncooperative or unwilling to cooperate with physical examination, or that may affect the evaluation of outcomes.
  4. Persistent systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 110 mmHg following active antihypertensive treatment.
  5. Severe hyperglycemia or hypoglycemia.
  6. Any of the following within 3 months prior to enrollment: acute ST-elevation myocardial infarction , and/or acute decompensated heart failure, and/or > 520 ms, and/or hospitalization or unplanned coronary intervention due to acute coronary syndrome, myocardial infarction, or cardiac arrest; or (NYHA) Class III/IV heart failure; or known ventricular tachycardia.
  7. History of severe hepatic impairment.
  8. History of severe renal insufficiency.
  9. Advanced or currently undergoing antineoplastic treatment.
  10. Female participants who are pregnant or breastfeeding, or female participants with a positive pregnancy test result at screening.
  11. Participation in another interventional clinical trial involving an drug or medical device (defined as having signed an form and received the investigational product/device) within 3 months prior to the screening visit.
  12. Terminal illness with an estimated of less than 1 year.
  13. Any other condition that, in the opinion of the investigator, renders the participant inappropriate for study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    HRS-4029 low dose

    Drug: HRS-4029

  • Experimental
    HRS-4029 medium dose

    Drug: HRS-4029

  • Experimental
    HRS-4029 high dose

    Drug: HRS-4029

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHRS-4029

    HRS-4029

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants With Modified Rankin Scale (mRS) Score ≤ 2

    The modified Rankin score (mRS) is a 6-point scale commonly used to assess disability due to stroke, with higher values indicating worse outcomes. 0 = No symptoms; 1 = No significant disability; 2 = Slight disability; 3 = Moderate disability; 4 = Moderately severe disability; 5 = Severe disability; 6 = Death.

    Time frame: Day 90

Secondary outcomes

  1. The Infarct Volume

    Time frame: 24 hours

  2. The Proportion of Participants With Improvement of 4 or more points, or return to the National Institutes of Health Stroke Scale (NIHSS) total score of 0 or 1

    The National Institutes of Health Stroke Score (NIHSS) is a 15-item scale that measures neurological deficit in acute stroke patients. Each item is ranked using a 3-, 4-, or 5-point scale, including allowances for items that cannot be scored due to the patient's condition, with higher scores indicating more severe deficit. Total scores range from 0-42, with higher scores indicating more severe deficits.

    Time frame: Day 10

  3. The Proportion of Participants With Modified Rankin Scale (mRS) score ≤ 1

    Time frame: Day 90

  4. Ordinal Modified Rankin Scale (mRS) Score

    Time frame: Day 90

  5. The Proportion of Participants With a Barthel Index (BI) Score ≥ 95

    The Barthel Index (BI) is a 10-item ordinal scale used to measure performance in activities of daily living (ADL) and mobility. The BI scoring range is from 0-100, with lower scores representing greater dependency.

    Time frame: Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 7 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 7 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, last on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Sep 29, 2026was Aug 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
Beijing Tiantan Hospital, Capital Medical University is now Recruiting
Nov 5, 2026
Start date
Aug 15, 2026→Sep 29, 2026 (actual)
moved 2 times, Oct 2, 2026 – Nov 5, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionThe Proportion of Participants With Modified Rankin Scale (mRS) Score ≤ 2: how it is measured was reworded
Oct 2, 2026
Contact
Study contact changed: j•••@hengrui.com · •••4134→j•••@hengrui.com · •••5401; x•••@hengrui.com · •••9350→x•••@hengrui.com · •••9350. See the current contact
Oct 2, 2026
Show all 2 updates
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    Beijing Tiantan Hospital, Capital Medical University is now Recruiting
    Start date Oct 2026→Sep 29, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 2, 2026
    Start date Aug 15, 2026→Oct 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionThe Proportion of Participants With Modified Rankin Scale (mRS) Score ≤ 2: how it is measured was reworded
    Contact Study contact changed: j•••@hengrui.com · •••4134→j•••@hengrui.com · •••5401; x•••@hengrui.com · •••9350→x•••@hengrui.com · •••9350. See the current contact
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07739160
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Sep 29, 2026
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Shengjie Zhang, MM
Contact
jiawen.xu.jx130@hengrui.com
+86 13612175401
Xiao Chen, CPM
Contact
xiao.chen.xc1@hengrui.com
+86 18861359350

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion